Taiwan urged to protect medical technology market with care financing reforms:
This article was originally published in Clinica
Taiwan has been called upon by the US to "revamp" its National Health Insurance (NHI) framework to reduce barriers to the introduction of new medical technologies. In a "white paper" issued on May 30, the American Chamber of Commerce (AMCHAM) in Taiwan says that the country's financial deficit is threatening the current success of the NHI. "Maintaining this high standard of healthcare for the general populace is becoming increasingly difficult-If no solution is found, the introduction of new medical technology will be sacrificed." Taiwan's ministry of economic affairs (MOEA) has welcomed AMCHAM's recommendations, which include tightening intellectual property protection, upgrading the public healthcare system and accelerating economic integration with China.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.